Impact of the RNF213 p.R4810K Variant on Endovascular Therapy for Large‐Vessel Occlusion Stroke
Background We investigated the impact of the ring finger protein 213 p.R4810K variant, a founder variant for moyamoya disease in East Asians, on endovascular therapy outcomes in patients with acute anterior‐circulation large‐vessel occlusion stroke in comparison with noncarriers. Methods Of the cons...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Stroke: Vascular and Interventional Neurology |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/SVIN.122.000396 |
| _version_ | 1797844161705017344 |
|---|---|
| author | Takeshi Yoshimoto Kanta Tanaka Junpei Koge Satoshi Saito Hiroshi Yamagami Yuriko Nakaoku Soshiro Ogata Kunihiro Nishimura Eriko Yamaguchi Tetsuya Chiba Daisuke Kawakami Masayuki Shiozawa Naruhiko Kamogawa Tsuyoshi Ohta Tetsu Satow Manabu Inoue Yorito Hattori Kazuo Washida Hiroharu Kataoka Jong‐Won Chung Oh Young Bang Kazunori Toyoda Masatoshi Koga Hirofumi Maruyama Masafumi Ihara |
| author_facet | Takeshi Yoshimoto Kanta Tanaka Junpei Koge Satoshi Saito Hiroshi Yamagami Yuriko Nakaoku Soshiro Ogata Kunihiro Nishimura Eriko Yamaguchi Tetsuya Chiba Daisuke Kawakami Masayuki Shiozawa Naruhiko Kamogawa Tsuyoshi Ohta Tetsu Satow Manabu Inoue Yorito Hattori Kazuo Washida Hiroharu Kataoka Jong‐Won Chung Oh Young Bang Kazunori Toyoda Masatoshi Koga Hirofumi Maruyama Masafumi Ihara |
| author_sort | Takeshi Yoshimoto |
| collection | DOAJ |
| description | Background We investigated the impact of the ring finger protein 213 p.R4810K variant, a founder variant for moyamoya disease in East Asians, on endovascular therapy outcomes in patients with acute anterior‐circulation large‐vessel occlusion stroke in comparison with noncarriers. Methods Of the consecutive patients with ischemic stroke admitted to our institute from 2011 to 2021, patients who underwent endovascular therapy for acute occlusion of the intracranial internal carotid artery or M1 segment of the middle cerebral artery were included. Outcomes were instant reocclusion, final modified Thrombolysis in Cerebral Infarction reperfusion ≥2b, and early reocclusion. Instant reocclusion was defined as the occurrence of reocclusion during the procedure, and early reocclusion was defined as reocclusion detected on magnetic resonance angiography within 2 weeks after the confirmation of successful reperfusion. Results Of the 277 patients analyzed (128 women; median age, 76 years), 10 patients (3.6%) carried the ring finger protein 213 p.R4810K variant. Variant carriers were younger (P=0.01) and more frequently had intracranial atherosclerotic disease‐related large‐vessel occlusion as a cause of acute large‐vessel occlusion (P<0.001) compared with noncarriers. Variant carriers showed a higher rate of instant reocclusion (70.0% versus 5.6%; P<0.001), but there were no significant intergroup differences in the final modified Thrombolysis in Cerebral Infarction ≥2b reperfusion rate between carriers and noncarriers (100.0% versus 81.6%, respectively; P=0.22). Early reocclusion was more frequent in variant carriers compared with noncarriers (60.0% versus 0.4%; P<0.001). Conclusions Instant and early reocclusions were more frequent in variant carriers who underwent endovascular therapy for acute anterior‐circulation large‐vessel occlusion compared with noncarriers. |
| first_indexed | 2024-04-09T17:17:53Z |
| format | Article |
| id | doaj.art-f6b1a8dfd96149729e3bfe62e3e5d985 |
| institution | Directory Open Access Journal |
| issn | 2694-5746 |
| language | English |
| last_indexed | 2024-04-09T17:17:53Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stroke: Vascular and Interventional Neurology |
| spelling | doaj.art-f6b1a8dfd96149729e3bfe62e3e5d9852023-04-19T11:15:14ZengWileyStroke: Vascular and Interventional Neurology2694-57462022-11-012610.1161/SVIN.122.000396Impact of the RNF213 p.R4810K Variant on Endovascular Therapy for Large‐Vessel Occlusion StrokeTakeshi Yoshimoto0Kanta Tanaka1Junpei Koge2Satoshi Saito3Hiroshi Yamagami4Yuriko Nakaoku5Soshiro Ogata6Kunihiro Nishimura7Eriko Yamaguchi8Tetsuya Chiba9Daisuke Kawakami10Masayuki Shiozawa11Naruhiko Kamogawa12Tsuyoshi Ohta13Tetsu Satow14Manabu Inoue15Yorito Hattori16Kazuo Washida17Hiroharu Kataoka18Jong‐Won Chung19Oh Young Bang20Kazunori Toyoda21Masatoshi Koga22Hirofumi Maruyama23Masafumi Ihara24Department of Neurology National Cerebral and Cardiovascular Center Suita JapanDepartment of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita JapanDepartment of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita JapanDepartment of Neurology National Cerebral and Cardiovascular Center Suita JapanDepartment of Stroke Neurology National Hospital Organization Osaka National Hospital Osaka JapanDepartment of Preventive Medicine and Epidemiology National Cerebral and Cardiovascular Center Suita JapanDepartment of Preventive Medicine and Epidemiology National Cerebral and Cardiovascular Center Suita JapanDepartment of Preventive Medicine and Epidemiology National Cerebral and Cardiovascular Center Suita JapanDepartment of Neurology National Cerebral and Cardiovascular Center Suita JapanDepartment of Neurology National Cerebral and Cardiovascular Center Suita JapanDivision of Analytical and Measuring Instruments Shimadzu Corporation Nakagyo‐ku Kyoto JapanDepartment of Clinical Neuroscience and Therapeutics Hiroshima University Hiroshima JapanDepartment of Clinical Neuroscience and Therapeutics Hiroshima University Hiroshima JapanDepartment of Neurosurgery National Cerebral and Cardiovascular Center Suita JapanDepartment of Neurosurgery National Cerebral and Cardiovascular Center Suita JapanDepartment of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita JapanDepartment of Neurology National Cerebral and Cardiovascular Center Suita JapanDepartment of Neurology National Cerebral and Cardiovascular Center Suita JapanDepartment of Neurosurgery National Cerebral and Cardiovascular Center Suita JapanDepartment of Neurology Samsung Medical Center Sungkyunkwan University School of Medicine Seoul KoreaDepartment of Neurology Samsung Medical Center Sungkyunkwan University School of Medicine Seoul KoreaDepartment of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita JapanDepartment of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita JapanDepartment of Clinical Neuroscience and Therapeutics Hiroshima University Hiroshima JapanDepartment of Neurology National Cerebral and Cardiovascular Center Suita JapanBackground We investigated the impact of the ring finger protein 213 p.R4810K variant, a founder variant for moyamoya disease in East Asians, on endovascular therapy outcomes in patients with acute anterior‐circulation large‐vessel occlusion stroke in comparison with noncarriers. Methods Of the consecutive patients with ischemic stroke admitted to our institute from 2011 to 2021, patients who underwent endovascular therapy for acute occlusion of the intracranial internal carotid artery or M1 segment of the middle cerebral artery were included. Outcomes were instant reocclusion, final modified Thrombolysis in Cerebral Infarction reperfusion ≥2b, and early reocclusion. Instant reocclusion was defined as the occurrence of reocclusion during the procedure, and early reocclusion was defined as reocclusion detected on magnetic resonance angiography within 2 weeks after the confirmation of successful reperfusion. Results Of the 277 patients analyzed (128 women; median age, 76 years), 10 patients (3.6%) carried the ring finger protein 213 p.R4810K variant. Variant carriers were younger (P=0.01) and more frequently had intracranial atherosclerotic disease‐related large‐vessel occlusion as a cause of acute large‐vessel occlusion (P<0.001) compared with noncarriers. Variant carriers showed a higher rate of instant reocclusion (70.0% versus 5.6%; P<0.001), but there were no significant intergroup differences in the final modified Thrombolysis in Cerebral Infarction ≥2b reperfusion rate between carriers and noncarriers (100.0% versus 81.6%, respectively; P=0.22). Early reocclusion was more frequent in variant carriers compared with noncarriers (60.0% versus 0.4%; P<0.001). Conclusions Instant and early reocclusions were more frequent in variant carriers who underwent endovascular therapy for acute anterior‐circulation large‐vessel occlusion compared with noncarriers.https://www.ahajournals.org/doi/10.1161/SVIN.122.000396endovascular therapyRNF213 p.R4810Kstroke |
| spellingShingle | Takeshi Yoshimoto Kanta Tanaka Junpei Koge Satoshi Saito Hiroshi Yamagami Yuriko Nakaoku Soshiro Ogata Kunihiro Nishimura Eriko Yamaguchi Tetsuya Chiba Daisuke Kawakami Masayuki Shiozawa Naruhiko Kamogawa Tsuyoshi Ohta Tetsu Satow Manabu Inoue Yorito Hattori Kazuo Washida Hiroharu Kataoka Jong‐Won Chung Oh Young Bang Kazunori Toyoda Masatoshi Koga Hirofumi Maruyama Masafumi Ihara Impact of the RNF213 p.R4810K Variant on Endovascular Therapy for Large‐Vessel Occlusion Stroke Stroke: Vascular and Interventional Neurology endovascular therapy RNF213 p.R4810K stroke |
| title | Impact of the RNF213 p.R4810K Variant on Endovascular Therapy for Large‐Vessel Occlusion Stroke |
| title_full | Impact of the RNF213 p.R4810K Variant on Endovascular Therapy for Large‐Vessel Occlusion Stroke |
| title_fullStr | Impact of the RNF213 p.R4810K Variant on Endovascular Therapy for Large‐Vessel Occlusion Stroke |
| title_full_unstemmed | Impact of the RNF213 p.R4810K Variant on Endovascular Therapy for Large‐Vessel Occlusion Stroke |
| title_short | Impact of the RNF213 p.R4810K Variant on Endovascular Therapy for Large‐Vessel Occlusion Stroke |
| title_sort | impact of the rnf213 p r4810k variant on endovascular therapy for large vessel occlusion stroke |
| topic | endovascular therapy RNF213 p.R4810K stroke |
| url | https://www.ahajournals.org/doi/10.1161/SVIN.122.000396 |
| work_keys_str_mv | AT takeshiyoshimoto impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT kantatanaka impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT junpeikoge impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT satoshisaito impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT hiroshiyamagami impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT yurikonakaoku impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT soshiroogata impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT kunihironishimura impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT erikoyamaguchi impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT tetsuyachiba impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT daisukekawakami impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT masayukishiozawa impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT naruhikokamogawa impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT tsuyoshiohta impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT tetsusatow impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT manabuinoue impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT yoritohattori impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT kazuowashida impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT hiroharukataoka impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT jongwonchung impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT ohyoungbang impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT kazunoritoyoda impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT masatoshikoga impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT hirofumimaruyama impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke AT masafumiihara impactofthernf213pr4810kvariantonendovasculartherapyforlargevesselocclusionstroke |